
Norman Ronald Rosenthal MD
Chief Scientific Officer North America Pharmaceuticals
Join to View Full Profile
11110 Stephalee LnRockville, MD 20852
Phone+1 301-770-5642
Fax+1 301-770-6019
Dr. Rosenthal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1978
Certifications & Licensure
- NJ State Medical License Current
- NY State Medical License 1979 - 2026
- MD State Medical License 1979 - 2025
- WA State Medical License 1987 - 2015
- FL State Medical License 1999 - 2013
- DC State Medical License 1999 - 2008
- American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 2 citationsCardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.David M Charytan, Kenneth W Mahaffey, Meg J Jardine, Christopher P Cannon, Bruce Neal
BMJ Open Diabetes Research & Care. 2023-06-01 - 7 citationsThe effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.Clare Arnott, Jingwei Li, Christopher P. Cannon, Dick de Zeeuw, Brendon L. Neuen
Diabetes, Obesity & Metabolism. 2021-07-01 - 69 citationsEffects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.Megumi Oshima, Brendon L. Neuen, Meg Jardine, George L. Bakris, Robert Edwards
The Lancet. Diabetes & Endocrinology. 2020-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: